Hangzhou Neoantigen Biotechnology co., LTD. entered into purchase agreement to raise CNY 50,000,000 in a round of funding on August 28, 2023. The transaction will include participation from new investor Boai NKY Medical Holdings Ltd. and will hold 11.1111% stake post completion of the transaction. The company registered capital will increase from CNY 1,044,823 to CNY 1,175,426.

The transaction has been been approved in the 4th meeting of the Boai NKY Medical Holdings Ltd. 5th directorate and does not need the shareholders? approval.